Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Ketoprofen). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Keto-A is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage Anti-inflammatory dosage: The recommended starting dose is 150 to 300 mg per day, given in 3 divided doses. Once the maintenance dosage has been established (usually 100 to 200 mg per day), the patient may be tried on a twice-daily dosing regimen. Alternatively, switching to the once-daily form at the same dosage may be considered. The recommended maximum daily dose is 300 mg. Management of pain and primary dysmenorrhea: The usual recommended dose is 25 to 50 mg every 6 to 8 hours as necessary. The total daily dose should not exceed 300 mg.
Side Effects
Blood and lymphatic system disorders: haemorrhagic anaemia is rare, while agranulocytosis, thrombocytopenia, bone marrow failure, haemolytic anaemia and leucopenia occur with unknown frequency. Immune system disorders: anaphylactic reactions, including shock, occur with unknown frequency. Psychiatric disorders: depression, hallucinations, confusion and altered mood occur with unknown frequency. Nervous system disorders: headache, dizziness and somnolence are uncommon; paraesthesia is rare; aseptic meningitis, convulsions, dysgeusia and vertigo occur with unknown frequency. Eye disorders: blurred vision is rare. Ear and labyrinth disorders: tinnitus is rare. Cardiac disorders: worsening of heart failure and atrial fibrillation occur with unknown frequency. Vascular disorders: hypertension, vasodilatation and vasculitis, including leukocytoclastic vasculitis, occur with unknown frequency. Respiratory, thoracic and mediastinal disorders: asthma is rare; bronchospasm occurs with unknown frequency, particularly in patients with known hypersensitivity to ASA and other NSAIDs. Gastrointestinal disorders: dyspepsia, nausea, abdominal pain and vomiting are common; constipation, diarrhoea, flatulence and gastritis are uncommon; stomatitis and peptic ulcer are rare; worsening of colitis and Crohn's disease, gastrointestinal haemorrhage and perforation, and pancreatitis occur with unknown frequency. Hepatobiliary disorders: hepatitis and raised transaminases are rare. Skin and subcutaneous disorders: rash and pruritus are uncommon; photosensitivity reaction, alopecia, urticaria, angioedema, and bullous eruption including Stevens-Johnson syndrome, toxic epidermal necrolysis and acute generalised exanthematous pustulosis occur with unknown frequency. Renal and urinary disorders: acute renal failure, tubulointerstitial nephritis, nephritic syndrome and abnormal renal function tests occur with unknown frequency. General disorders and administration site conditions: oedema is uncommon. Metabolism and nutritional disorders: hyponatraemia and hyperkalaemia occur with unknown frequency. Investigations: weight gain is rare.
Cautions & Contraindications
Warnings & Precautions
Oral Forms: NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease), as their condition may be exacerbated. At the start of treatment, renal function must be carefully monitored in patients with heart failure, cirrhosis and nephrosis, in patients receiving diuretic therapy, and in patients with chronic renal impairment, particularly if the patient is elderly. In these patients, administration of Profenid-CR may induce a reduction in renal blood flow caused by prostaglandin inhibition and lead to renal decomposition. Caution is required in patients with a history of hypertension and/or mild to moderate congestive heart failure, as fluid retention and oedema have been reported in association with NSAID therapy. An increased risk of atrial fibrillation has been reported in association with the use of NSAIDs. Hyperkalemia may occur, especially in patients with underlying diabetes, renal failure, and/or concomitant treatment with hyperkalemia-promoting agents. Potassium levels must be monitored under these circumstances. As with other NSAIDs, in the presence of an infectious disease it should be noted that the anti-inflammatory, analgesic and antipyretic properties of Profenid-CR may mask the usual signs of infection progression, such as fever. In patients with abnormal liver function tests or with a history of liver disease, transaminase levels should be evaluated periodically, particularly during long-term therapy. Rare cases of jaundice and hepatitis have been described with Profenid-CR. If visual disturbances such as blurred vision occur, treatment should be discontinued. The use of NSAIDs may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulty conceiving or who are undergoing investigation of infertility, withdrawal of the NSAID should be considered.
Contraindications
Ketoprofen must not be used in patients with a history of hypersensitivity reactions, such as asthma attacks or other allergic-type reactions, to ketoprofen, aspirin (ASA) or other NSAIDs. Severe and, in rare cases, fatal anaphylactic reactions have been reported in these patients. Ketoprofen is also contraindicated in severe heart failure, in active peptic ulcer or bleeding or a history of either, in patients with a history of gastrointestinal bleeding or perforation linked to earlier NSAID treatment, in severe liver impairment, in severe kidney impairment, in the third trimester of pregnancy, and, for the rectal form, in rectitis or a history of rectal bleeding.